Retatrutide in the UAE · Research-Use Reference

Retatrutide in the UAE

What it is, whether it’s available or legal in the UAE, the trial evidence, and the research formats documented here.

Retatrutide (LY-3437943) is an investigational GLP-1/GIP/glucagon triple-agonist peptide. It is not approved or registered for medical use in the UAE by MoHAP, the FDA, or the EMA, and remains in Phase 3 trials. This page explains its UAE availability and legal status, summarises the published TRIUMPH evidence, and documents the research formats Remy Peptides supplies for in-vitro laboratory research only.

  • Investigational · Phase 3 TRIUMPH
  • Not MoHAP / FDA / EMA approved
  • Janoshik-tested batches
  • GLP-1 / GIP / glucagon agonist

For wider market context, see the Retatrutide Dubai guide, the Retatrutide Abu Dhabi guide, and the approval-status tracker; for the full UAE catalogue, research peptides UAE. To order any format for research use, use the product pages. Updated July 6, 2026.

UAE legal & approval status →
TRIUMPH trial evidence → View COA →
Retatrutide research pen — UAE supply, Janoshik-verified batch RETP002
Remy Peptides Pen · Batch RETP002
Remy Peptides · UAE
Research Only
Retatrutide research pen — UAE supply, Janoshik-verified batch RETP002
Verification Snapshot
Independent third-party batch test at a glance
Purity
99.262%
Batch
RETP002
Per Click
0.1mg
Tested
04 Nov 2025

Supplied for in-vitro laboratory research only. Material must not be frozen and should remain protected from light.

Quick Answer

Retatrutide UAE: what it is, its status, and how it’s supplied.

Retatrutide (LY-3437943), often shortened to reta, is an investigational triple-agonist peptide studied for obesity and metabolic disease across Eli Lilly’s Phase 3 TRIUMPH programme. It is not approved or registered as a medicine in the UAE — it has no MoHAP, FDA, or EMA marketing authorisation — so it reaches UAE researchers as a research-use compound, not a prescription product. As a research material it is documented here in six formats (prefilled pens and lyophilised vials), each released against an independent Janoshik Certificate of Analysis; indicative research-use pricing runs AED 350–2,000 per unit. For the adjacent dual-agonist, compare the tirzepatide 40mg research vial. For Research Use Only — not for human or veterinary use.

On this page: UAE legal & approval status, the TRIUMPH trial evidence, the research formats, and batch COA documentation.

Retatrutide UAE at a glance
  • Regulatory status: not approved or registered as a UAE medicine (no MoHAP, FDA, or EMA authorisation); supplied research-use only under MoHAP Circular 17/2022.
  • Formats available: six research formats — 30mg, 20mg, 10mg, and 40mg prefilled pens plus 10mg and 40mg vials (five formats in stock — three pens plus both vials; only the 40mg pen out of stock).
  • Price span: AED 350–2,000 per unit across formats; the flagship 30mg pen is AED 1,600, with volume tiers from AED 1,300/pen.
  • Delivery: same-day Dubai dispatch, next-day across other emirates, insulated 2–8°C cold-chain (free over AED 1,000).
  • COA / purity proof: each released batch carries an independent Janoshik Certificate of Analysis; flagship batch RETP002 tests at 99.262% HPLC purity.

Ordering for research use

The flagship Retatrutide 30mg Pen (batch RETP002, 99.262% HPLC purity) is AED 1,600 per unit, with volume tiers from AED 1,300/pen. All six formats are compared below. For Research Use Only.

Order the 30mg Pen → All research formats →
UAE Status

Is retatrutide legal or approved in the UAE? Its current regulatory status.

Quick answer: Retatrutide is not approved or registered as a medicine anywhere — it holds no UAE MoHAP, US FDA, or EMA marketing authorisation and remains in Eli Lilly’s Phase 3 TRIUMPH programme. In the UAE it is supplied only as a research-use material under MoHAP Circular 17/2022, not as a prescription drug.

Retatrutide is an investigational compound: it is not a registered UAE medicine and holds no marketing approval anywhere in the world. In the UAE it is handled under research-use rules rather than as a prescription drug. Here is what that means for its approval, legal framing, and availability.

Approval status

Retatrutide is not approved by the UAE MoHAP, the US FDA, or the EMA. It remains in Eli Lilly’s Phase 3 TRIUMPH programme and is not registered as a UAE pharmacy medicine for obesity or any other indication.

Legal & research-use framing

Because it is unapproved, retatrutide is supplied only as a research-use material under UAE MoHAP Circular 17/2022 — for in-vitro laboratory research, not for human or veterinary use. UAE health authorities have publicly warned against unauthorised retatrutide weight-loss products marketed to consumers.

Availability

As a research compound it is available to UAE researchers through documented suppliers that publish batch COAs; it is not available as an approved prescription. Individuals can access retatrutide for treatment only by enrolling in a supervised clinical trial.

Is retatrutide approved in the UAE?

No. Retatrutide holds no UAE MoHAP, US FDA, or EMA marketing authorisation and is not a registered pharmacy medicine. It remains investigational in Eli Lilly’s Phase 3 TRIUMPH programme, and in the UAE it is supplied only as a research-use material under MoHAP Circular 17/2022.

Where can I buy retatrutide in the UAE?

Remy Peptides supplies research-use retatrutide from Dubai stock and ships across the UAE, with three of the four pen formats currently in stock (the 40mg pen is out of stock). Review the six documented formats and their batch COAs on this page, verify the official channel via contact verification, then order through the individual product pages. For in-vitro laboratory research only.

Is retatrutide better than semaglutide?

In published trial data, retatrutide’s triple-agonist design reported a higher mean weight change than single-agonist semaglutide — about 24% at 48 weeks in the phase 2 study versus roughly 15% for semaglutide over comparable durations. Retatrutide remains investigational, so this reflects trial observations, not a treatment claim.

Format Comparison

The research formats supplied in the UAE: 30mg, 20mg, 10mg, and 40mg pens plus 10mg and 40mg vials.

Remy Peptides lists six Retatrutide formats in the UAE: 30mg pen (batch RETP002, 99.262% HPLC purity), 20mg pen (RET-20-C-2604-001, 99.841%), 10mg pen (COA pending), 40mg pen (RET-20-V-2604-001, 99.741%), 10mg vial (RET-20-V-2604-001, 99.741%), and 40mg vial (RT-40-V-001, 99.692%, sterility-tested). Five of the six listed retatrutide formats are currently in stock — the 30mg, 20mg and 10mg pens plus the 10mg and 40mg vials. Only the 40mg pen is currently out of stock. Public Janoshik COAs are at the COA library. Same molecule across formats—seal level, batch proof, reconstitution burden, and AED-per-mg are what differ.

Format Documentation Reconstitution Total Peptide Price from AED/mg Link
Retatrutide 30mg Pen Batch RETP002 · public COA None — sealed pen 30mg AED 1,300 AED 43–53/mg View 30mg pen → In stock
Retatrutide 20mg Pen Batch RET-20-C-2604-001 · public COA None — sealed pen 20mg AED 1,000 AED 50–60/mg View 20mg pen → In stock
Retatrutide 10mg Pen COA pending publication None — sealed pen 10mg AED 600 AED 60–70/mg View 10mg pen → In stock
Retatrutide 10mg Vial Batch RET-20-V-2604-001 · public COA Bacteriostatic water required 10mg lyophilised AED 350 AED 35/mg View 10mg vial → In stock
Retatrutide 40mg Vial Batch RT-40-V-001 · public COA Bacteriostatic water required 40mg lyophilised AED 900 AED 22.50–25/mg View details → In stock
Retatrutide 40mg Pen Batch RET-20-V-2604-001 · public COA None — sealed pen 40mg AED 1,700 AED 43–50/mg View details → Out of stock

Click counts, mg-per-click conversions, and protocol math live on the reconstitution and click calculator and the mg-to-click lookup. Phase 3 titration windows are documented in the Phase 3 titration schedule.

30mg pen

Longest sealed-device route. Janoshik batch RETP002 published. No mixing step.

20mg pen

Highest published purity in the catalog (99.841%). Sealed pen. Lower entry price than the flagship.

10mg pen

Smallest sealed-pen ticket. Lowest absolute price for a no-reconstitution route. Batch COA pending publication.

10mg vial

Entry-tier vial. Listed at AED 350/vial and in stock. Same Janoshik vial-line batch as the 40mg.

40mg vial

Largest lyophilised vial format in the catalog. Best if the workflow needs a 40mg vial and can handle reconstitution.

40mg pen

Largest sealed-pen format — 40mg in a prefilled FlexiPen, Janoshik vial-line batch RET-20-V-2604-001 at 99.741%. No reconstitution; currently out of stock.

Trial Evidence

What the TRIUMPH trials show. Triple receptor mechanism, endpoints, and reported safety signals.

Retatrutide is a triple receptor agonist acting on the GLP-1, GIP, and glucagon pathways — engaging three metabolic receptors across three hormone pathways involved in appetite regulation, energy balance, and glucose handling. It acts on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon signalling; this triple receptor mechanism is studied for its influence on appetite, food intake, and overall metabolic function and metabolic health. In Eli Lilly’s Phase 3 TRIUMPH programme, published readouts report endpoints across body weight, visceral fat, insulin sensitivity, HbA1c, and blood pressure, with the compound given once weekly by subcutaneous injection in the trial protocol. Earlier Phase 2 data published in the New England Journal of Medicine reported weight reduction of up to 24.2% in study participants at the highest dose; by comparison, semaglutide targets one receptor while retatrutide targets three. On safety, the most commonly reported events involve the gastrointestinal system — nausea, diarrhea, vomiting, constipation, reduced appetite, and changes in bowel habits, concentrated during dose escalation. In the Phase 3 TRIUMPH-1 readout, dysesthesia was reported in up to 12.5% of participants at the 12 mg study dose, and adverse-event-driven discontinuation rose with dose, from 4.1% at 4 mg to 6.9% at 9 mg and 11.3% at 12 mg, versus 4.9% on placebo. No serious organ-level safety signals have been identified in trials, but ongoing research and ongoing monitoring still matter because retatrutide remains investigational. This describes clinical-trial data, not instructions for use.

In the phase 2 trial (NEJM 2023), participants receiving the highest retatrutide dose showed a mean body-weight reduction of about 24% at 48 weeks.

Full mechanism, the trial-by-trial breakdown, and the literature trail live in the retatrutide research hub; see also the triple-agonist comparison and the approval-status tracker. Remy Peptides supplies retatrutide for in-vitro laboratory research only.

CredentialsVerified Apr 2026
Lab Janoshik Analytical

Independent third-party verification.

Purity 99.262%

HPLC verified, batch-linked.

Logistics Cold-chain

Insulated 2–8°C from Dubai stock.

Delivery 2–4hr Dubai

Same-day Dubai, next-day UAE.

Documents Full COA library

Batch RETP002 published online.

Price · Purity · Batch

Retatrutide pricing, purity & batch reference. All six formats, all batch IDs.

Quick answer: Research-use retatrutide in the UAE spans AED 350–2,000 per unit across six formats. The flagship 30mg pen is AED 1,600 for a single unit, with volume tiers from AED 1,300/pen; the 10mg vial starts at AED 350 and the 40mg pen reaches AED 2,000. Each released batch carries an independent Janoshik HPLC Certificate of Analysis.

Single-unit AED price, third-party HPLC purity, batch number, AED-per-mg at the best tier, and a direct COA link for each documented Retatrutide format.

Format Purity (HPLC purity) Batch AED / unit (1-pack) AED / mg (best tier) COA
Retatrutide 30mg Pen 99.262% RETP002 AED 1,600 AED 43/mg View COA →
Retatrutide 20mg Pen 99.841% RET-20-C-2604-001 AED 1,200 AED 50/mg View COA →
Retatrutide 10mg Pen Pending publication Pending publication AED 600 AED 50/mg Pending publication
Retatrutide 40mg Vial 99.692% RT-40-V-001 AED 1,000 AED 22.50/mg View COA →
Retatrutide 40mg Pen 99.741% RET-20-V-2604-001 AED 2,000 AED 43/mg View COA →
Retatrutide 10mg Vial 99.741% RET-20-V-2604-001 AED 350 AED 35/mg View COA →

The Retatrutide 30mg Pen and 20mg Pen are distinct product lines, not a single product priced two ways — different molds, different fill specs, different batches. The vials are documented per batch too: the 10mg vial on RET-20-V-2604-001, and the 40mg vial on its own sterility-tested batch RT-40-V-001 with a full microbial panel plus heavy metals, residual TFA, and bacterial endotoxin — documentation rarely published by sellers in this category.

Before You OrderVerification snapshot
Highest Published Purity 99.841%

Batch RET-20-C-2604-001 (20mg Pen).

Lab Janoshik Analytical

Independent HPLC verification.

Vial Sterility Panel Full panel

Heavy metals, TFA, endotoxin published.

Documents COA library →

Per-batch certificates online.

Dispatch Cold-chain Dubai

2–8°C insulated, same-day.

Use Research only

For in-vitro laboratory research only.

Supply & Ordering

How retatrutide is supplied for research use. Pricing reference and where to order.

Remy Peptides holds retatrutide in Dubai and ships it across the UAE strictly as a research-use material. Indicative pricing runs AED 350–2,000 per unit depending on format and quantity — the 10mg vial from AED 350, the 30mg pen around AED 1,300–1,600, the 40mg pen up to AED 2,000 — with selected multi-unit tiers. Each released batch carries an independent Janoshik COA, and UAE delivery is tracked (free over AED 1,000; AED 50 flat below that). To place a research-use order, open the individual product pages or the order page, and confirm the official channel first via contact verification. For Research Use Only — not for human or veterinary use.

Per-format price, purity, and batch IDs are in the pricing reference above; reconstitution and click math live on the calculator.

Retatrutide COA UAE

Verify the batch.
Verify the channel.

Every retatrutide format released in the UAE ships with a matching Janoshik Analytical Certificate of Analysis. The 30mg pen sample below is one of four published batch reports — the 20mg pen, the 10mg vial, and the sterility-tested 40mg vial each have their own. Confirm the batch in the COA library, then verify WhatsApp, Telegram, and Instagram through the contact-verification page before transferring funds. Material is supplied under UAE MoHAP Circular 17/2022 research-use framing.

Certificate of Analysis — Janoshik Test Report for Retatrutide Batch RETP002 by Remy Peptides
Laboratory
Janoshik Analytical
Batch (sample shown)
RETP002
Purity
99.262%
Date Tested
04 Nov 2025
Format Batch Purity (HPLC purity) COA
Retatrutide 30mg Pen RETP002 99.262% View COA →
Retatrutide 20mg Pen RET-20-C-2604-001 99.841% View COA →
Retatrutide 10mg Pen Pending Pending Publication pending
Retatrutide 10mg Vial RET-20-V-2604-001 99.741% View COA →
Retatrutide 40mg Vial RT-40-V-001 99.692% View COA →
Open COA library → Verify contact channels → Research standards →

Compliance reference: UAE MoHAP Circular 17/2022 — in-vitro research-use framing for non-pharmacy investigational compounds.

Pick Your Path

What do you need first?

Need dosage detail?

Phase 3 titration schedule and study-design context. Lives in the research library, not on this format page.

Open dosage guide →

Need legality?

UAE legal context for research peptides, MoHAP framing, and import boundaries.

Open legality brief →

Need approval status?

FDA, EMA, and MoHAP approval timeline plus the live TRIUMPH trial tracker.

Open approval tracker →

Need supplier checklist?

Step-by-step buyer checklist: COA validation, batch verification, channel checks.

Open buying guide →

Need click math?

Reconstitution and click calculator. Dose math lives there, not on this format page.

Open calculator →

Need mechanism & literature?

The retatrutide research hub — covers the triple-agonist mechanism, showing how retatrutide targets three receptors—GLP-1, GIP, and glucagon—involved in appetite regulation and metabolic processes, plus trial map, side-effect data, and the full literature trail.

Open research hub →

Auf Deutsch?

German-language research-use page for “Retatrutide kaufen” — six formats, Janoshik COA proof, and bulk (ab 200 Pens) enquiry.

Retatrutide kaufen →
Direct answers

Retatrutide UAE — availability, legality, and approval.

Direct answers to the questions most asked about retatrutide in the UAE. For ordering logistics see the product pages; for wider market context, the Retatrutide Dubai guide.

Is retatrutide available in the UAE?

Direct answer: Not as an approved medicine. Retatrutide has no MoHAP, FDA, or EMA authorisation and is still in Phase 3 trials, so it is not sold as a UAE pharmacy product. It is available to UAE researchers as a research-use compound: Remy Peptides documents six formats — 30mg, 20mg, 10mg, and 40mg pens plus 10mg and 40mg vials — held in Dubai, each released against an independent Janoshik COA. For in-vitro laboratory research only, not for human or veterinary use.

Compare the formats: format reference table.

Is retatrutide legal in the UAE?

Direct answer: Retatrutide is not a registered or approved medicine in the UAE, so it cannot be marketed or used as a treatment. It is permitted only as a research-use material under UAE MoHAP Circular 17/2022 — in-vitro laboratory research, not human or veterinary use. UAE health authorities have warned the public against unauthorised retatrutide weight-loss products.

Legal context: are peptides legal in Dubai?

How do I get retatrutide in the UAE, and when will it be approved?

Direct answer: For research use, retatrutide is obtained from a documented supplier that publishes batch COAs — order through the product pages after confirming the official channel via contact verification. For treatment, the only legitimate access is enrolment in a supervised clinical trial. No approval date is confirmed: retatrutide is still completing the Phase 3 TRIUMPH programme before any regulatory filing. For in-vitro laboratory research only under MoHAP Circular 17/2022.

Approval timeline: is retatrutide approved?

Common Questions

Retatrutide UAE — Research, COA and delivery FAQ

Is Retatrutide available in the UAE?
Retatrutide is available in the UAE through Remy Peptides for in-vitro laboratory research use only. Stock is held in Dubai and dispatched cold-chain — same-day to Dubai and next-day to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, and Umm Al Quwain. Retatrutide is investigational, not registered as a UAE pharmacy product, and not approved for clinical use. For the full market context, see the Retatrutide Dubai guide.
What is retatrutide (LY-3437943)?
Retatrutide (LY-3437943) is an investigational multi-agonist peptide studied across GLP-1, GIP, and glucagon receptor pathways. It acts through three hormone pathways involved in appetite regulation, appetite control, metabolic function, and energy expenditure, which is why retatrutide appears in obesity and weight-management research literature. Published trial data reports body-weight, insulin-sensitivity, visceral-fat, HbA1c, and blood-pressure endpoints tied to this metabolic signalling. Remy Peptides supplies retatrutide formats for in-vitro laboratory research only, with Janoshik batch documentation linked from the COA library. For mechanism, trial background, and the full literature trail, see the retatrutide research hub.
How fast is delivery in Dubai?
Dubai orders confirmed before 4 PM receive same-day delivery via temperature-controlled courier. Typical hand-off window is 2–4 hours from confirmation. Stock dispatches from our Al Barsha, Dubai location with insulated packaging and 2–8°C maintenance throughout transit. Delivery is free on orders of AED 1,000+ (AED 50 flat under AED 1,000).
Is Retatrutide approved in the UAE?
No. Retatrutide is not approved by UAE MoHAP, the FDA, or the EMA. It remains investigational and is currently in Eli Lilly's Phase 3 TRIUMPH trial programme. Material is supplied for in-vitro laboratory research only and falls under UAE MoHAP Circular 17/2022 research-use framing. Other agents may follow separate regulatory pathways, but retatrutide is not an approved treatment. See the full timeline in Is Retatrutide Approved?.
What is Batch RETP002?
RETP002 is the batch identifier for the current Retatrutide stock. It was independently tested by Janoshik Analytical on 04 Nov 2025 and verified at 99.262% purity by HPLC purity. The full Certificate of Analysis is published in the COA library and is included with every shipment. Confirm the batch before you transfer funds — standard supplier hygiene.
Is Retatrutide Dubai delivery same-day?
Yes. Retatrutide Dubai delivery is same-day for orders confirmed before 4 PM. Delivery reaches every Dubai district, including Marina, Downtown, Business Bay, JLT, JBR, Palm Jumeirah, Al Barsha, Dubai Hills, and Dubai Silicon Oasis, and is free on orders of AED 1,000+ (AED 50 flat under AED 1,000). Outside Dubai, all UAE emirates receive next-day delivery from Dubai stock.
How much does Retatrutide cost in the UAE?
Live Retatrutide pricing in the UAE runs AED 350 to AED 2,000 per unit across the six formats. The 30mg pen — one of three pen formats currently in stock — is AED 1,600 single, AED 1,450/pen at 2-pack, and AED 1,300/pen at 5+ pack. The 10mg vial is in stock; AED 350 across displayed pack sizes. The 40mg vial is in stock; AED 1,000 single or 2-pack and AED 900/vial at 5+ pack. The 40mg Pen is currently out of stock; AED 2,000 (1-pack), AED 1,850 per pen in a 2-pack, and AED 1,700 per pen in a 5+ pack are reference prices. Selected formats show 2-pack and 5+ pack tiers. See the full price + batch matrix. UAE delivery is free on orders of AED 1,000+ (AED 50 flat under AED 1,000). Because of its investigational status, pricing is speculative and not directly comparable to approved medicines; many queries are driven by research interest rather than clinical use.
Where can I buy Retatrutide in the UAE?
Remy Peptides is a Dubai-based research supplier shipping Retatrutide across the UAE. Stock is COA-verified by Janoshik Analytical, dispatched cold-chain from Al Barsha, Dubai — same-day to Dubai and next-day to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, and Umm Al Quwain. Material is supplied for in-vitro laboratory research only under UAE MoHAP Circular 17/2022 framing.
Retatrutide UAE: what formats are available?
Remy Peptides lists six Retatrutide formats in the UAE: 30mg pen (batch RETP002, 99.262% HPLC purity), 20mg pen (RET-20-C-2604-001, 99.841%), 10mg pen (COA pending), 40mg pen (RET-20-V-2604-001, 99.741%), 10mg vial (RET-20-V-2604-001, 99.741%), and 40mg vial (RT-40-V-001, 99.692%). Five of the six listed retatrutide formats are currently in stock — the 30mg, 20mg and 10mg pens plus the 10mg and 40mg vials. Only the 40mg pen is currently out of stock. Public Janoshik COAs are at the COA library. Compare seal level, reconstitution, and AED/mg in the format comparison table. For Research Use Only.
Which Retatrutide format has the highest published purity?
The Retatrutide 20mg Pen at 99.841% HPLC purity, batch RET-20-C-2604-001, Janoshik-verified. The 30mg Pen flagship sits at 99.262% HPLC purity on batch RETP002. Pens and vials are separate product lines with their own batches and COAs.
Which Retatrutide format should I choose — 30mg pen, 20mg pen, 10mg vial, or 40mg vial?
Pick on four axes — seal level, batch proof, reconstitution burden, and AED-per-mg. The 30mg pen is the longest sealed-pen route. The 20mg pen has the highest published purity. The 10mg vial is the entry-tier reconstituted route at AED 350 and is currently in stock. The 10mg pen is the smallest sealed-pen ticket and is currently in stock. The 40mg vial is the largest lyophilised vial format, listed at AED 900–1,000/vial depending on quantity and currently in stock. The 40mg pen is the largest sealed-pen format, listed at AED 1,700–2,000 and currently out of stock. For click counts and reconstitution math, see the reconstitution and click calculator and the mg-to-click lookup.
What side effects or safety signals were reported in retatrutide trials?
Clinical research has reported gastrointestinal adverse events such as nausea, diarrhea, vomiting, and constipation, especially during trial escalation phases. In the Phase 3 TRIUMPH-1 readout, dysesthesia was reported in up to 12.5% of participants at the 12 mg study dose, and adverse-event-driven discontinuation rose with dose, from 4.1% at 4 mg to 6.9% at 9 mg and 11.3% at 12 mg, versus 4.9% on placebo. The full safety dataset and trial-by-trial breakdown live in the retatrutide research hub. Remy Peptides supplies material for in-vitro laboratory research only.
How is Retatrutide administered in clinical research?
In Eli Lilly's Phase 3 TRIUMPH trial programme, retatrutide is administered to participants once weekly by subcutaneous injection. That describes the clinical-trial protocol, not instructions for use. The trial timeline and phase status are tracked on the approval status page. Remy Peptides supplies the compound for in-vitro laboratory research only and does not provide dosing protocols.
How does Retatrutide work in research models?
Retatrutide is studied as a triple receptor agonist acting on GLP-1, GIP, and glucagon pathways. In simplified terms, glucagon-like peptide-1 (GLP-1) activity is linked to satiety and gastric emptying, glucose-dependent insulinotropic polypeptide (GIP) contributes to post-meal insulin response and may interact with adipose tissue, and glucagon signalling relates to stored energy use and changes in metabolic rate. Those pathways are associated with appetite regulation, gastric-emptying signals, energy balance, insulin-sensitivity markers, and body-composition endpoints in published trials. Current research is characterising body weight, visceral fat, cardiometabolic markers, and safety across the TRIUMPH programme. Remy Peptides does not position retatrutide for human or veterinary use. See the retatrutide research hub for the full mechanism and trial overview.
Who is Retatrutide being studied for?
Retatrutide is being studied in clinical trials involving participants with obesity and related metabolic endpoints, including research interest in body weight reduction and improved insulin sensitivity. Trial inclusion criteria, monitoring, and endpoints are set by the study sponsors and investigators. The TRIUMPH-1 through TRIUMPH-4 protocols and their endpoints are summarised in the retatrutide research hub. Outside those research settings, retatrutide is supplied for in-vitro laboratory research only.
How is product quality and sourcing ensured?
All released Remy Peptides retatrutide batches are tied to documented quality controls and independent Janoshik Analytical testing: 30mg pen RETP002 at 99.262% HPLC purity, 20mg pen RET-20-C-2604-001 at 99.841%, 10mg vial RET-20-V-2604-001 at 99.741%, and the sterility-tested 40mg vial RT-40-V-001 at 99.692%. The 40mg vial carries a full microbial sterility panel (TAMC/TYMC pass) plus heavy metals, residual TFA, and bacterial endotoxin. Contact verification is published so buyers can confirm the official channel before transferring funds.
Where are your peptides manufactured?
Our peptides are produced by a cGMP-compliant manufacturing partner using fully automated synthesis equipment and advanced analytical instruments, including UPLC and high-resolution mass spectrometry, with API testing performed in an ISO/IEC 17025-accredited laboratory. Every batch is then independently verified by Janoshik Analytical before release, so you rely on third-party data rather than vendor-only claims. Supplied for research use only.
What is the research status of Retatrutide?
Ongoing Phase 3 studies (TRIUMPH-1, -2, -3, -4) are evaluating retatrutide across obesity, body-weight, safety, and metabolic regulation endpoints. Retatrutide remains an investigational peptide under ongoing research rather than routine clinical use. Understanding its investigational status is important: it is not approved for clinical use and is supplied for research purposes only under UAE MoHAP Circular 17/2022 framing. See the approval status overview for the live trial tracker.
What should be considered when handling Retatrutide research material?
Research-use handling decisions should be made with appropriate laboratory oversight, focusing on storage conditions, reconstitution where applicable, and chain-of-custody documentation. Material must not be frozen and should remain protected from light. Consistency in storage and handling is important to maintain integrity of the research material across protocols. Reconstitution math for the vial line lives on the reconstitution and click calculator; batch-specific HPLC purity and sterility data is published in the COA library. Material is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
How does Retatrutide fit into global peptide research?
Peptide research in weight-management and metabolic-regulation fields is evolving worldwide, with GLP-1 mono-agonists, GLP-1/GIP dual-agonists, and triple agonists like retatrutide occupying distinct research positions by mechanism and trial endpoint. Interpreting this landscape requires attention to regulatory approval status by jurisdiction, the role of investigational compounds, and how trial data translates across populations. See the triple-agonist comparison for a side-by-side view.

Verify the evidence before you decide

1. Check the approval status  ·  2. Read the trial evidence  ·  3. Review the batch COAs

Approval status Research hub Review COA library →
Janoshik COA verified Phase 3 investigational MoHAP 17/2022 research-use

Remy Peptides · For in-vitro laboratory research only. Not for human or veterinary use. Research Use Only

COA Library
Tracked Cold-Chain Delivery
Research Use Only
Retatrutide 30mg Pen Research use only
Order